[Radiologically Guided Interventional Therapies for the Treatment of Neuroendocrine Tumors]

Overview

Journal Radiologie (Heidelb)

Specialty Radiology

Date 2024 May 18

PMID 38761204

Authors

C G Radosa

H Nebelung

F Schon

R T Hoffmann

Affiliations

Soon will be listed here.

Abstract

Background: The majority of patients with neuroendocrine tumors (NET) develop liver metastases during the course of the disease, significantly impacting prognosis and quality of life.

Clinical Issue: Radiologically guided interventional therapies, such as thermal ablation, transarterial embolization (TAE)/chemoembolization (TACE), and selective internal radiotherapy (TARE), can play a crucial role in the treatment of metastatic NET.

Data: Due to the rarity of the disease, the majority of evidence is based on retrospective studies. For thermal ablation, the complete response rates ranging from 31.6 to 95.3% depending on the study. No significant differences in outcomes were found between TAE, TACE, and TARE. In several studies, all intra-arterial procedures led to a reduction of tumor-related symptoms and achieved disease control.

Conclusion: Thermal ablation can be used as a curative therapy in oligometastatic patients with nonresectable liver metastases from NETs. In cases of disseminated liver metastases, intra-arterial therapy using TAE, TACE, or TARE can be employed.

References

Atwell T, Charboneau J, Que F, Rubin J, Lewis B, Nagorney D . Treatment of neuroendocrine cancer metastatic to the liver: the role of ablative techniques. Cardiovasc Intervent Radiol. 2005; 28(4):409-21. DOI: 10.1007/s00270-004-4082-6. View

Barat M, Cottereau A, Kedra A, Dermine S, Palmieri L, Coriat R . The Role of Interventional Radiology for the Treatment of Hepatic Metastases from Neuroendocrine Tumor: An Updated Review. J Clin Med. 2020; 9(7). PMC: 7408651. DOI: 10.3390/jcm9072302. View

Berber E, Flesher N, Siperstein A . Laparoscopic radiofrequency ablation of neuroendocrine liver metastases. World J Surg. 2002; 26(8):985-90. DOI: 10.1007/s00268-002-6629-5. View

Boudreaux J, Klimstra D, Hassan M, Woltering E, Jensen R, Goldsmith S . The NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the Jejunum, Ileum, Appendix, and Cecum. Pancreas. 2010; 39(6):753-66. DOI: 10.1097/MPA.0b013e3181ebb2a5. View

Cazzato R, Hubele F, De Marini P, Ouvrard E, Salvadori J, Addeo P . Liver-Directed Therapy for Neuroendocrine Metastases: From Interventional Radiology to Nuclear Medicine Procedures. Cancers (Basel). 2021; 13(24). PMC: 8699378. DOI: 10.3390/cancers13246368. View

Clift A, Thomas R, Frilling A . Developments in interventional management of hepatic metastases from neuroendocrine tumours. Best Pract Res Clin Endocrinol Metab. 2023; 37(5):101798. DOI: 10.1016/j.beem.2023.101798. View

DSouza D, Golzarian J, Young S . Interventional Liver-Directed Therapy for Neuroendocrine Metastases: Current Status and Future Directions. Curr Treat Options Oncol. 2020; 21(6):52. DOI: 10.1007/s11864-020-00751-x. View

Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y . Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States. JAMA Oncol. 2017; 3(10):1335-1342. PMC: 5824320. DOI: 10.1001/jamaoncol.2017.0589. View

De Baere T, Deschamps F, Tselikas L, Ducreux M, Planchard D, Pearson E . GEP-NETS update: Interventional radiology: role in the treatment of liver metastases from GEP-NETs. Eur J Endocrinol. 2014; 172(4):R151-66. DOI: 10.1530/EJE-14-0630. View

10.

Dorffel Y, Wermke W . Neuroendocrine tumors: characterization with contrast-enhanced ultrasonography. Ultraschall Med. 2009; 29(5):506-14. DOI: 10.1055/s-2008-1027555. View

11.

Engelman E, Leon-Ferre R, Naraev B, Sharma N, Sun S, ODorisio T . Comparison of transarterial liver-directed therapies for low-grade metastatic neuroendocrine tumors in a single institution. Pancreas. 2014; 43(2):219-25. PMC: 4307836. DOI: 10.1097/MPA.0000000000000030. View

12.

Fiore F, Del Prete M, Franco R, Marotta V, Ramundo V, Marciello F . Transarterial embolization (TAE) is equally effective and slightly safer than transarterial chemoembolization (TACE) to manage liver metastases in neuroendocrine tumors. Endocrine. 2014; 47(1):177-82. DOI: 10.1007/s12020-013-0130-9. View

13.

Frilling A, Clift A, Braat A, Alsafi A, Wasan H, Al-Nahhas A . Radioembolisation with 90Y microspheres for neuroendocrine liver metastases: an institutional case series, systematic review and meta-analysis. HPB (Oxford). 2019; 21(7):773-783. DOI: 10.1016/j.hpb.2018.12.014. View

14.

Frilling A, Modlin I, Kidd M, Russell C, Breitenstein S, Salem R . Recommendations for management of patients with neuroendocrine liver metastases. Lancet Oncol. 2014; 15(1):e8-21. DOI: 10.1016/S1470-2045(13)70362-0. View

15.

Gillams A, Cassoni A, Conway G, Lees W . Radiofrequency ablation of neuroendocrine liver metastases: the Middlesex experience. Abdom Imaging. 2005; 30(4):435-41. DOI: 10.1007/s00261-004-0258-4. View

16.

Hellman P, Ladjevardi S, Skogseid B, Akerstrom G, Elvin A . Radiofrequency tissue ablation using cooled tip for liver metastases of endocrine tumors. World J Surg. 2002; 26(8):1052-6. DOI: 10.1007/s00268-002-6663-3. View

17.

Hicks R, Kwekkeboom D, Krenning E, Bodei L, Grozinsky-Glasberg S, Arnold R . ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasia: Peptide Receptor Radionuclide Therapy with Radiolabeled Somatostatin Analogues. Neuroendocrinology. 2017; 105(3):295-309. DOI: 10.1159/000475526. View

18.

Jia Z, Wang W . Yttrium-90 radioembolization for unresectable metastatic neuroendocrine liver tumor: A systematic review. Eur J Radiol. 2018; 100:23-29. DOI: 10.1016/j.ejrad.2018.01.012. View

19.

Lawhn-Heath C, Fidelman N, Chee B, Jivan S, Armstrong E, Zhang L . Intraarterial Peptide Receptor Radionuclide Therapy Using Y-DOTATOC for Hepatic Metastases of Neuroendocrine Tumors. J Nucl Med. 2020; 62(2):221-227. DOI: 10.2967/jnumed.119.241273. View

20.

Lee E, Pachter H, Sarpel U . Hepatic arterial embolization for the treatment of metastatic neuroendocrine tumors. Int J Hepatol. 2012; 2012:471203. PMC: 3272914. DOI: 10.1155/2012/471203. View